摘要
近半个世纪,我国肺癌发病率和病死率均居全部恶性肿瘤之首。将来的20年,我国的肺癌病发数和病死数还在持续上升,传统的癌症治疗方法正面临着一个新的艰巨的挑战。近年来肺癌的分子病理指导下的个体化靶向治疗作为一项极具潜力的新方法已逐渐成为肺癌临床标准治疗的一部分,有着传统化疗及免疫治疗无可匹敌的优越性。肺癌分子靶向的诊断和治疗正逐渐成为常规治疗以及最佳个体化治疗的重要依据。表皮生长因子受体已成为炙手可热的临床肺癌治疗的分子靶点。
Nearly half century, the lung cancer incidence and mortality are among the top of the all the malignant tu-mor. In the future 20 years, the number of lung disease and deaths will also continue to rise in our country, the tradi-tional cancer treatments are facing a new challenge. The molecular pathology of lung cancer in recent years under the guidance of individual target therapy as a potential new method has gradually become a part of the lung cancer clinical standard management has incomparable advantages of traditional chemotherapy and immunotherapy. The diagnosis and treatment of lung cancer molecular target is becoming a important basis of routine treatment and individualized treat-ment. The epidermal growth factor receptor has become the hottest clinical molecular targets for lung cancer treatment.
出处
《中国医药导报》
CAS
2014年第36期148-152,共5页
China Medical Herald
基金
国家自然科学基金(编号81450047)
